C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.

Saved in:
Bibliographic Details
Title: C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.
Authors: de Boer ECW; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.; Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands., Jalink M; Department of Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands., Delvasto-Nuñez L; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands., Meulenbroek EM; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands., Baas I; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands., Janssen SR; Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands., Folman CC; Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands., Gelderman KA; Sanquin Diagnostic Services, Amsterdam, The Netherlands., Wouters D; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Engel MD; Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands., de Haas M; Department of Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands.; Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Kersten MJ; Department of Hematology, Amsterdam University Medical Centers, Location University of Amsterdam, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands., Jongerius I; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.; Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands., Zeerleder S; Department of Hematology, Luzerner Kantonsspital, Luzern, Switzerland.; Department for BioMedical Research, University of Bern, Bern, Switzerland., Vos JMI; Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam University Medical Centers, Location University of Amsterdam, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.
Source: Blood advances [Blood Adv] 2023 Jul 11; Vol. 7 (13), pp. 3128-3139.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2022009402